Introduction/Overview
Natural products, as an important source of drug discovery, play an irreplaceable role in the history of human disease prevention and treatment. Among them, triterpenoids have always been a hot topic in medicinal chemistry and pharmacology research due to their structural diversity and wide range of biological activities. Ganoderma lucidum, as a traditional medicinal fungus, is known as the "fairy grass". Its pharmacological active substances are mainly concentrated in polysaccharides and triterpenoids. Lucidian Acid E2 (LA-E2) is a lanostane triterpenoid acid with significant biological activity isolated from Ganoderma lucidum. Since its discovery, it has gradually become a research focus in the field of natural product pharmacology due to its unique chemical structure and enormous potential in immune regulation. This article aims to systematically review the chemical structure, plant origin, pharmacological activity, multi-target immunomodulatory mechanism, pharmacological evaluation, and clinical application prospects of E2 gibberellic acid, in order to provide comprehensive scientific references for the in-depth research and development of this compound.
Chemical structure and physicochemical properties
The chemical name of E2 gibberellic acid is (4 β, 8 β, 9 β, 10 α, 14 β, 17 β, 20S) -3,7,11,15,23-pentacarbonyl-4,4,8,10,14-pentamethyl-20- (2-methyl-1-oxo-2-butenyl) -9,19-cyclolanostan-24-en-26-onic acid, with a CAS number of 98665-17-9. Structurally, LA-E2 belongs to highly oxidized lanostane triterpenes, with multiple carbonyl and hydroxyl groups on its parent nucleus, and an α, β - unsaturated carbonyl structure (2-methyl-1-oxo-2-butenyl) and a terminal carboxyl group on its side chain. These functional groups, especially unsaturated carbonyl groups, are the key pharmacophores that interact with biomolecules (such as proteins) and produce pharmacological activity.
Its molecular weight is 516.6310, and the calculated lipid water partition coefficient (LogP) is 2.8132, indicating that the compound has moderate to high lipophilicity. The topological polar surface area (TPSA) is 135.0400 Å ², reflecting the presence of multiple polar groups (such as carboxyl and carbonyl groups) in the molecule. The predicted water solubility value is relatively low (about 0.0267 mg/mL), which is consistent with the properties of most triterpenoids, suggesting that solubilization strategies may need to be considered in formulation development. Preliminary pharmacological risk assessment shows that LA-E2 has a low ability to cross the blood-brain barrier, which limits its direct application in central nervous system diseases, but may also reduce potential neurotoxic risks. In addition, the risk of hERG inhibition is' no ', and the Ames test predicted a value of 0.0 (indicating no mutagenicity), providing favorable early clues for its safety evaluation.
Plant sources and extraction methods
Gibberellic acid E2 mainly comes from the fruiting bodies, mycelium, or spore powder of the porous fungus Ganoderma Lucidum (Leyss. ex Fr.) Karst. Different regions, cultivation conditions, growth stages, and varieties of Ganoderma lucidum (such as Ganoderma lucidum and Ganoderma lucidum) can all affect the content of LA-E2. Usually, the use of modern analytical techniques such as HPLC-MS for chemical fingerprint analysis of Ganoderma lucidum extracts is a key step in identifying and quantifying LA-E2.
The extraction of LA-E2 from Ganoderma lucidum materials is often carried out using organic solvent extraction method. Due to LA-E2 being a triterpenoid acid with moderate polarity, commonly used extraction solvents include methanol, ethanol, ethyl acetate, or alcohol water mixed solvents in different proportions. The classic extraction process is as follows: the dried and crushed Ganoderma lucidum material is subjected to reflux extraction or ultrasound assisted extraction with an appropriate solvent, and the extracted liquids are combined and concentrated under reduced pressure to obtain the crude extract. Subsequently, the crude extract needs to undergo systematic separation and purification. Technologies such as silica gel column chromatography, reverse phase silica gel column chromatography (such as ODS), and preparative high-performance liquid chromatography (pre HPLC) are commonly used for stepwise separation and purification. In recent years, supercritical CO ₂ extraction technology has also been attempted for the extraction of triterpenoids from Ganoderma lucidum, due to its advantages such as low temperature and no solvent residue. However, parameters need to be optimized to improve the selectivity of target triterpenoid acids.
Pharmacological activity research
Numerous in vitro and in vivo pharmacological studies have shown that the core pharmacological activity of gibberellic acid E2 is concentrated in immunomodulation And extend to related fields such as anti-inflammatory and anti-tumor.
-
Immune regulatory effect This is the most highly anticipated activity of LA-E2. Research has shown that LA-E2 has the potential for "bidirectional regulation" of the immune system. LA-E2 can promote the activation and proliferation of immune cells in immunosuppressed or suppressed states. For example, research has found that it can enhance the activity of T lymphocytes and B lymphocytes. On the other hand, in models of excessive immune activation or autoimmune diseases, LA-E2 exhibits immunosuppressive effects, such as inhibiting the excessive activation of T cells and the explosive release of inflammatory factors. This seemingly contradictory bidirectional regulatory effect actually reflects its ability to finely regulate the balance of the immune network by acting on multiple immune related targets.
-
anti-inflammatory effect LA-E2 has shown significant anti-inflammatory effects in various acute and chronic inflammation models. It can effectively inhibit the production of nitric oxide (NO), prostaglandin E2 (PGE2), and various pro-inflammatory cytokines (such as TNF - α, IL-1 β, IL-6) by macrophages stimulated by inflammatory factors such as lipopolysaccharide (LPS). This anti-inflammatory activity is closely related to its immune regulatory effect and is the basis for its intervention in inflammatory and immune related diseases.
-
antitumor activity The anti-tumor activity of LA-E2 is partially attributed to its immunomodulatory effect, which inhibits tumor growth by activating the body's anti-tumor immune response. In addition, some studies also suggest that LA-E2 has a direct cytotoxic effect on some tumor cell lines (such as liver cancer and breast cancer cells) or can induce apoptosis, inhibit cell migration and invasion. Its anti-tumor mechanism may involve multiple pathways, including regulating the cell cycle and activating apoptotic signaling pathways.
-
Other activities There are also a few studies reporting that LA-E2 may have hepatoprotective and antioxidant activities, which are associated with its anti-inflammatory and cell protective effects, but further systematic research is needed to confirm this.
Mechanism of action and molecular targets
The immunomodulatory effect of E2 gibberellic acid is not achieved through a single target, but as a multi-target regulator that acts on multiple key nodes in the immune signaling network. According to existing research, its related targets mainly include:
-
Pattern recognition receptors and innate immune signals：TLR4 It is an important receptor for identifying pathogen related molecular patterns such as LPS. Research has shown that LA-E2 can interfere with TLR4 signaling, thereby inhibiting downstream nuclear factor kappa B（NF-κB）Pathway activation. NF - κ B (derived from)NFKB1 The encoded subunit is its key component and is a core transcription factor that regulates inflammation and immune response. LA-E2 reduces the expression of various pro-inflammatory factors (such as TNF - α, IL-6) and chemokines by inhibiting the degradation of I κ B or nuclear translocation of NF - κ B.
-
Cytokine signaling and JAK/STAT pathway This pathway is the core of cytokine function. LA-E2 has been proven to have an impact STAT3 and STAT4 Phosphorylation and activation. STAT3 is often continuously activated in the tumor microenvironment and autoimmune diseases, promoting cell proliferation and inflammation; STAT4 is associated with Th1 cell differentiation and IFN - γ production. The inhibition of LA-E2 on them helps correct abnormal immune responses. Meanwhile, it can also regulate the expression of key cytokines, such as reducing pro-inflammatory cytokines IFN-γ、IL-2 And may upregulate anti-inflammatory effects IL-10 Thus regulating the balance of Th1/Th2 and Th17/Treg.
-
T cell function and immune tolerance LA-E2 has a direct impact on adaptive immunity, especially T cell function. It can inhibit key signals for T cell activation and affect the function of regulatory T cells (Tregs).FOXP3 LA-E2 is a specific transcription factor and functional master gene of Treg, and may indirectly affect the expression of FOXP3, thereby enhancing the immunosuppressive function of Treg. In addition, it may also affect co stimulatory molecules such as CTLA4 CTLA4 is a negative regulator of T cell activation and plays a crucial role in maintaining immune tolerance.
-
Growth factor signal：TGF-β1 It is a multifunctional cytokine that plays a role in immune suppression, fibrosis, and tumor progression. The effect of LA-E2 on the TGF - β 1 signaling pathway may be one of its mechanisms for regulating immunity and anti fibrosis, but the specific mode of action remains to be elucidated.
In summary, the mechanism network of action of LA-E2 can be summarized as follows: by inhibiting innate immune inflammatory signals such as TLR4/NF - κ B, regulating JAK/STAT mediated cytokine effects, and directly or indirectly affecting T cell activation, differentiation, and function (such as through FOXP3, CTLA4, etc.), the imbalanced immune state (whether overactivated or dysfunctional) is ultimately regulated towards homeostasis. This multi-target characteristic gives it unique advantages in treating complex immune disorders.
Evaluation of drug properties and pharmacokinetics
Although E2 gibberellic acid exhibits outstanding pharmacological activity, its drug like and pharmacokinetic properties are the key factors determining its successful development as a drug.
According to the physical and chemical parameters mentioned earlier, LA-E2 meets the basic requirements of the Rule of Five, but its moderate LogP value and low water solubility are the main challenges for oral absorption. Lipophilicity may be beneficial for its transmembrane absorption, but low water solubility can limit its dissolution in gastrointestinal fluids, becoming the rate limiting step in absorption. Therefore, in the development of formulations, it may be necessary to use solubilization techniques such as solid dispersions, nanocrystals, liposomes, or cyclodextrin inclusion complexes to improve their bioavailability.
At present, there are relatively limited research reports on the pharmacokinetics of LA-E2 system. Based on its structural characteristics, it can be inferred that after oral administration, its absorption may be incomplete and the variability may be significant; May undergo extensive metabolism in the body, such as glucuronic acid binding of carboxyl groups, sulfation or oxidation of hydroxyl groups, and phase I and phase II metabolic reactions; Its distribution may be concentrated in tissues and organs with abundant blood flow, but the blood-brain barrier permeability is poor; The main pathways of excretion may be through bile and feces. Clear key PK parameters such as absolute bioavailability, half-life, distribution volume, and clearance rate need to be systematically studied in animal models (rats, dogs, etc.) using standardized radioactive labeling or high-sensitivity LC-MS/MS biological analysis methods. In addition, its potential for interaction with common drug metabolizing enzymes such as CYP450 isoenzymes also needs to be evaluated.
In terms of safety, preliminary computer predictions suggest that there is no risk of hERG inhibition or genetic toxicity, but this must be ultimately confirmed through standardized GLP toxicology experiments (such as acute toxicity, repeated administration toxicity, reproductive toxicity, etc.).
Clinical application prospects and prospects
The multi-target and bidirectional immune regulation properties of E2 from Ganoderma lucidum have brought broad application prospects in the treatment of various refractory immune related diseases.
-
Autoimmune diseases Such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, etc. The common feature of these diseases is that the immune system attacks its own tissues abnormally. LA-E2 is expected to restore immune tolerance and control disease progression by inhibiting overactivated T cells, pro-inflammatory factors (such as NF - κ B, STAT3), and possibly promoting Treg function (such as FOXP3).
-
Organ transplantation and graft-versus-host disease (GVHD)Used as an immunosuppressant. LA-E2 may enhance efficacy and reduce toxicity when used in combination with traditional immunosuppressants such as tacrolimus and cyclosporine A by inhibiting IL-2 signaling, T cell proliferation, and activation (involving pathways such as CTLA4).
-
Adjuvant drugs for tumor immunotherapy On the one hand, its direct anti-tumor cell activity may play an adjuvant therapeutic role; On the other hand, what may be more important is its immunomodulatory effect. LA-E2 may be used to improve the tumor immune suppressive microenvironment, for example, by inhibiting STAT3 signaling to reduce the recruitment and function of myeloid derived suppressor cells (MDSCs) and regulatory T cells (Tregs), thereby enhancing the efficacy of adoptive cell therapy (such as CAR-T) or immune checkpoint inhibitors (such as anti-PD-1 antibodies).
-
Chronic inflammatory diseases: such as chronic hepatitis, pulmonary fibrosis, atherosclerosis, etc. Its anti-inflammatory and potential anti fibrotic effects (possibly by regulating TGF - β 1) provide new intervention ideas for these diseases.
However, pushing LA-E2 into clinical practice still faces many challenges: firstly, it needs to solve the formulation difficulties of low water solubility and oral bioavailability. Secondly, it is necessary to complete systematic and standardized preclinical pharmacodynamic (in animal models closer to human diseases), pharmacokinetic, and toxicological studies to clarify their therapeutic window and safety. Finally, its multi-target mechanism of action is both advantageous and complex, requiring more precise elucidation of its main targets and pathways in different pathological states to achieve precise medication. Future research can focus on developing efficient and environmentally friendly extraction and purification processes; Design and synthesize derivatives or prodrugs to optimize PK properties; Using systems biology and network pharmacology methods to deeply analyze its "compound target pathway disease" network; Explore its combination application strategy with existing standard therapeutic drugs.
Conclusion
Chizhi acid E2, as an important bioactive triterpenoid acid in Ganoderma lucidum, has become a promising star molecule in the field of natural product drug development due to its unique chemical structure and excellent multi-target immune regulatory activity. From inhibiting TLR4/NF - κ B inflammatory signaling to regulating JAK/STAT pathway and T cell function, its mechanism network is becoming increasingly clear, laying a solid scientific foundation for its application in autoimmune diseases, tumor immunotherapy and other fields. Although there are still gaps and challenges in drug development, systematic pharmacokinetics, and toxicology research, with the continuous development of modern pharmacy, medicinal chemistry, and pharmacology technologies, these bottlenecks are expected to be overcome one by one. The continuous and in-depth research on E2 in Ganoderma lucidum not only helps to develop new immunomodulatory drugs derived from traditional Chinese medicine, but also further enriches our scientific understanding of the complex biological effects of natural triterpenoids, and promotes the modernization and internationalization of traditional Chinese medicine.
